Press

TransEnterix Inc. has secured $55 million in a second round of institutional financing, paving the way for the company to manufacture and market its revolutionary laparoscopic surgical platform.
Full Story >

Officials at TransEnterix introduced the company’s revolutionary single-port, multi-channel laparoscopic SPIDER™ System at the Society of Laparoendoscopic Surgeons’ annual meeting last week.
Full Story >

TransEnterix’s revolutionary laparoscopic surgical platform that allows surgeons to perform minimally invasive abdominal procedures entirely through the umbilicus, leaving no visible scar, has been recognized as an “Innovation of the Year” by the Society of Laparoendoscopic Surgeons.
Full Story >

Whether single-port surgery or NOTES is the next true revolution in surgical procedures, TransEnterix believes it has the answer to both.
Full Story (PDF) >

Research Triangle Park, NC: September 24, 2008 - TransEnterix, an early-stage, privately-held medical device company focused on advanced minimally invasive surgery, announced today that the Board of Directors has named Todd M. Pope the Company’s first President and Chief Executive Officer. Mr. Pope has spent nearly 20 years in the medical device market with experience in cardiovascular, peripheral vascular, neurovascular, and laparoscopic surgery.
Full Story >

Abbott's new absorbable stent could change heart surgery and revive a $5 billion business. Read the PDF of the full article for more on Synecor's role in this medical innovation.
Full Story (PDF) >

Portola Valley, CA - January 8, 2008 - Synergy Life Science Partners, LP, a venture capital limited partnership focused on investments in emerging medical device technologies, today announced the successful completion of fundraising for its debut fund with an aggregate of $143 million in committed capital. The firm has closed on six investments to date.
Full Story >

Research Triangle Park, NC - December 31, 2007 - Synecor, LLC and SV Life Science Advisers, LLC announce today the first round of institutional financing for TransEnterix, Inc., a Synecor-founded company focused to pioneer and deliver novel, less-invasive tools and techniques for high volume gastro-intestinal surgical procedures. The first round of institutional financing secures for TransEnterix $21 million of raised and committed funds. The capital will be used to deliver the initial product platforms and further develop the next generation product platforms of TransEnterix.
Full Story >

Research Triangle Park, NC - July 17, 2007 - Synecor, LLC, a privately held business generator with a history of innovating disruptive medical technologies in immense life science markets for the foundation of new company creation, today announced the appointment of R. Frederick McCoy, Jr. to the newly created position of Vice-Chairman of the Board of Directors, effective July 2007. Mr. McCoy has more than 25 years of experience in the life sciences field and was most recently the President of Guidant, Cardiac Rhythm Management from May 2000 until his retirement in March 2006, pending the acquisition of Guidant Corporation by Boston Scientific Corporation.. : Full Story >

Research Triangle Park , NC - January 29, 2007 - InnerPulse, Inc, a privately held company developing unique technologies for the treatment of abnormal heart rhythms, announced today the closing of $50 million in new equity financing. The new capital will be used for the completion of the Company's novel implantable defibrillator and to support the infrastructure required to advance the Company from its early developmental phase to human clinical trials and commercialization.. : Full Story >

Research Triangle Park, NC - June 26, 2006 - InnerPulse, Inc, a privately held company developing unique technologies for the treatment of abnormal heart rhythms, announced today that it will move into a new 19,000-square-foot complex in Research Triangle Park in mid-July.  The new facility will accommodate its growing research and development activities and the upcoming commercialization of its first product, an innovative implantable defibrillator that can be placed in the body quickly and without surgery.  InnerPulse, Inc. was formerly called Interventional Rhythm Management, Inc.. : Full Story >

Indianapolis, Ind. and Santa Clara, Calif. — March 9, 2006 — Guidant Corporation (NYSE: GDT) today announced enrollment of the first patient in a first-in-man clinical trial designed to evaluate the safety of a fully bioabsorbable everolimus eluting stent platform for the treatment of coronary artery disease. The trial, called ABSORB, will enroll up to 60 patients in Belgium, Denmark, France, New Zealand, Poland and The Netherlands. : Full Story >

Research Triangle Park, NC - May 12, 2005 - IRM, Inc., an early stage cardiology company dedicated to the management of patients with cardiac arrhythmias and heart failure, announced today that it has raised $20 Million in Series B Financing. : Full Story >

Menlo Park, CA – January 31, 2005 – BaroSense Inc., a privately-held medical device company specializing in the minimally invasive treatment of obesity, announces that it has secured $10 million in Series B financing led by new investor RWI Group.  Other participating investors include Invesco Private Capital and existing investors, Frazier Healthcare Ventures and Delphi Ventures. : Full Story >

Research Triangle Park, NC – January 12, 2005 – Interventional Rhythm Management Inc. today announces its revolutionary design for cardiac electrophysiology devices, such as implantable defibrillators and pacemakers. IRM's ground-breaking design allows implantable defibrillators and pacemakers to be completely introduced and implanted within the vascular system without major surgery. : Full Story >

Indianapolis, Indiana & Santa Clara, California - April 20, 2004 - Guidant Corporation today announced the $6 million purchase of the remaining stake in a company developing fully bioabsorbable drug eluting stent platforms. These new stents in development are designed to be fully absorbed by vascular tissue following the restoration of blood flow in patients with coronary artery disease. The initial 51 percent stake was acquired for $10 million in the first quarter of 2003. Under the terms of the original agreement, Guidant will also make payments upon the achievement of certain regulatory milestones. Guidant has completed a 28-day animal study of a bioabsorbable drug eluting stent platform, providing initial data on dosing, safety, and mechanical properties of the stent. : Full Story >

Research Triangle Park, NC - December 18, 2003 - IRM, Inc., an early stage cardiology company dedicated to the management of patients with cardiac arrhythmias and heart failure, announced that it has raised $15.1 Million in Series A Financing. Headquartered in Research Triangle Park, North Carolina, IRM, Inc. will utilize the proceeds to establish and expand its operations. The financing was led by Delphi Ventures and Frazier Healthcare. : Full Story >

INDIANAPOLIS, Apr 1, 2003 (BUSINESS WIRE) -- Guidant Corporation (NYSE:GDT), a world leader in the treatment of cardiac and vascular disease, today announced that Guidant will acquire an early-stage company founded by Synecor, LLC, a medical technology generator of new life sciences companies based in Research Triangle Park, North Carolina, and Menlo Park and Santa Rosa, Calif. The venture is working to develop new, fully bioabsorbable vascular stent platforms that will be safely absorbed by tissue following the restoration of blood flow in patients with coronary artery disease. : Full Story >

Menlo Park, CA and Research Triangle Park, NC - September 20, 2002 - BaroSense Inc., a medical device company specializing in the minimally invasive treatment of obesity, announces that it has secured $6.2 million in Series A financing led by Frazier Healthcare Ventures and Delphi Ventures. : Full Story >

Incubators are hot and as their numbers multiply, so do the number of different models and approaches that these development partners take. The second of a two-part series. : Full Story (PDF) >

Dec 11, 2000 - SyneCor, LLC, announces that it has secured $10.5 million in financing led by Frazier Healthcare and Delphi Ventures. : Full Story >